HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zierz, S. Articles by Engel, A. G. Search for Related Content PubMed PubMed Citation Articles by Zierz, S. Articles by Engel, A. G.

Are there two forms of carnitine palmitoyltransferase in muscle?

Department of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, MN.

Mitochondria were isolated from rat skeletal muscle, heart, and liver and from human skeletal muscle. The distribution of CPT I and CPT II was studied by measuring CPT activity and malonyl-CoA sensitivity before and after disruption of the mitochondria. Neither sonication, freezing and thawing, nor detergent treatment increased CPT activity in heart or skeletal muscle mitochondria, but these procedures did increase CPT activity in liver mitochondria. These results cannot be attributed to different kinetics of CPTI and II to palmitoyl-CoA or carnitine, or to different effects of electrolytes on CPTI and II. Sensitivity to inhibition by malonyl-CoA also failed to distinguish convincingly between CPT I and II in skeletal muscle. Because the presence of CPT I and II in muscle cannot be ascertained, the notion of a selective CPT I or II deficiency in muscle cannot be entertained.

Address correspondence and reprint requests to Dr. Engel, Mayo Clinic, Rochester, MN 55905.

Supported by NIH Grant NS6277, a Research Center Grant from the Muscular Dystrophy Association, and by the Mogg fund.

Received August 18, 1986. Accepted for publication in final form January 20, 1987.